EGFR and gastric cancer: Numerous articles have pointed out that the aberrant expression of EGFR-AS1 is involved in the progression of diverse diseases, such as lung cancer (37–40), cervical cancer (41, 42), glioma (43, 44), bladder cancer (45, 46), kidney cancer (47, 48), head and neck cancer (49–51), gastric cancer (52), colorectal cancer (53), liver cancer (54), uterine cancer (55), preeclampsia (56), gestational diabetes mellitus (57), and cryptorchidism (58).